Trillium Therapeutics stock nearly triples after buyout deal with Pfizer valued at $2.26 billion – MarketWatch

Shares of Trillium Therapeutics Inc.
TRIL,
+3.92%
nearly tripled in premarket trading Monday, skyrocketing 189.3%, after the immuno-oncology company announced an agreement to be acquired by Pfi… [+704 chars]